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Abstract 
Purpose: Experimental studies suggest that phytoestrogen intake alters cancer and cardiovascular risk.  This study 
investigated the associations of urinary phytoestrogens with total cancer (n=79), cardiovascular (n=108), and all-
cause (n=290) mortality among 5,179 participants in the continuous National Health and Nutrition Examination 
Survey (1999-2004). 
Methods: Urinary phytoestrogens were measured using high performance liquid chromatography with tandem mass 
spectrometric detection. Survival analysis was performed to evaluate hazard ratios (HRs) and 95% confidence 
intervals (CIs) for each of the three outcomes in relation to urinary phytoestrogens. 
Results: After adjustment for confounders, higher urinary concentrations of total enterolignans were associated with 
a reduced risk of death from cardiovascular disease (HR for tertile 3 vs. tertile 1: 0.48; 95% CI: 0.24, 0.97), whereas 
higher urinary concentrations of total isoflavones (HR for tertile 3 vs. tertile 1: 2.14; 95% CI: 1.03, 4.47) and 
daidzein (HR for tertile 3 vs. tertile 1: 2.05; 95% CI: 1.02, 4.11) were associated with an increased risk.  A reduction 
in all-cause mortality was observed for elevated urinary concentrations of total enterolignans (HR for tertile 3 vs. 
tertile 1: 0.65; 95% CI: 0.43, 0.96) and enterolactone (HR for tertile 3 vs. tertile 1: 0.65; 95% CI: 0.44, 0.97). 
Conclusions: Some urinary phytoestrogens were associated with cardiovascular and all-cause mortality in a 
representative sample of the U.S. population.  This is one of the first studies that used urinary phytoestrogens as 
biomarkers of their dietary intake to evaluate the effect of these bioactive compounds on the risk of death from 
cancer and cardiovascular disease. 
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Introduction 
Cardiovascular disease and cancer are the leading causes of death in the United States [1] and many other 
developed countries throughout the world [2].  In the United States, 597,689 cardiovascular deaths and 574,743 
cancer deaths occurred in 2010 [1].  On a global scale, cardiovascular disease was estimated to account for over 13.2 
million deaths in 2011 [2], and total cancers claimed an estimated 8.2 million lives in 2012 [3].  To prevent the 
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development of cancer and cardiovascular disease, it is necessary to identify their risk factors, particularly 
modifiable ones.  One such modifiable factor is diet.  
Phytoestrogens are a group of non-steroidal plant metabolites.  The principal classes of phytoestrogens include 
isoflavones and lignans.  Isoflavones abound in soy products, legumes, and chick peas [4,5], and lignans primarily 
originate from seed oils, whole grain cereals, and beans [6].  Isoflavones found in soy products include genistein, 
daidzein, and glycitein [7], with these compounds arising after metabolism by the gut bacteria of the glycoside 
conjugates [8].  Daidzein can be further converted into two endogenous metabolites, equol and O-
desmethylangolensin, with individual variation in the metabolism of daidzein in populations [9,10].  Lignans 
commonly consumed by humans include enterolactone and enterodiol [11].  Differences in the biochemistry and 
food sources of individual phytoestrogens requires investigation of both the overall effect of total phytoestrogens as 
a single family of bioactive compounds and the independent effect of each phytoestrogen in relation to disease risk. 
 A growing body of experimental evidence suggests that it is biologically plausible that phytoestrogen intake 
may modulate the risk of cancer and cardiovascular disease [12-15].  Phytoestrogens can induce biologic responses 
due to their structural similarity to 17β-estradiol when they are consumed in the diet [16].  The biologic responses 
from phytoestrogens include estrogenic, anti-estrogenic, anti-oxidative, anti-viral, anti-bacterial, and anti-
proliferative effects [11].  It has been found that the potential beneficial effect of phytoestrogens on some hormone-
related cancers [17,18] is mediated through their competitive binding to estrogen receptors [19,20].  While estradiol 
exhibits an equal affinity to both α and β receptors (ERα and ERβ), phytoestrogens show a stronger affinity to ERβ 
[21].  For example, genistein has an approximately 30-fold greater affinity to the ERβ, and therefore may cause 
some clinical effects by selectively triggering this particular receptor [21].  Administration of phytoestrogens 
reduced serum testosterone levels in rats, an established risk factor for prostate cancer [12,22].  It was also found 
that soy phytoestrogens reversed severe pulmonary hypertension and prevented heart failure in the same animals 
[13].   
Despite experimental evidence, few epidemiologic studies have examined the associations between 
phytoestrogen intake and cancer or cardiovascular mortality in Western populations.  Previous studies have focused 
on a few sites of cancer, mainly prostate [23,24] and breast [25,26], yielding mixed results.  Little is known about 
the association between phytoestrogen intake and cardiovascular disease [27], although it is considered a promising 
area of research for cardiovascular disease prevention [28].  The consumption of soy products is lower in Western 
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countries than in Asian countries [18,29]. However, several studies have reported a considerable between-person 
variation in phytoestrogen intake in Western populations [30,31].  This suggests that it is methodologically feasible 
to investigate the effect of phytoestrogens on health and disease in non-Asian countries.  Several studies have shown 
that urinary concentrations of phytoestrogens are reliable, although modest, biomarker of phytoestrogen intake in 
both Asian and Western populations [11,32-36].  Significant positive correlations have been observed between usual 
intake of phytoestrogens and their urinary concentrations (e.g. r=0.54 for isoflavones and r=0.40 for lignans in a 
Canadian study [33] and r=0.31 for isoflavones in a Hawaii study [34].  Correlations of similar magnitude have also 
been identified between soy intake and urinary phytoestrogens among Seventh-day Adventists (individuals with a 
wide range of soy intake) [35] and Minnesota residents [36].  To date, no epidemiologic studies have evaluated the 
associations between phytoestrogen intake and total cancer, cardiovascular, and all-cause mortality in a nationally 
representative sample of the U.S. population.  Therefore, the present study investigated this research question using 
data on urinary excretion of total and individual phytoestrogens as well as total cancer, cardiovascular, and all-cause 
mortality, previously collected from the continuous National Health and Nutrition Examination Survey (NHANES). 
Subjects and methods 
Study population 
Data analyzed in this study were obtained from the NHANES for the years 1999-2004 and the NHANES linked 
public-use mortality file.  The mortality file was created from a follow-up study of mortality that matched records 
from the individual years of the NHANES study with data in the National Death Index (NDI) through December 31, 
2006 [37].  These data sources were selected because urinary phytoestrogen data for this six-year period only have 
been linked to mortality data in the NDI.  NHANES is a cross-sectional study conducted by the Center for Disease 
Prevention and Control to assess the health and nutritional status of the general U.S. population.  Data collection and 
sampling procedures for NHANES have been described in detail elsewhere [38].  Sample weights were applied to 
the data through the calculation of a six-year weight variable according to the guidelines from the National Center 
for Health Statistics (NCHS) when combining two or more two-year cycles of the continuous NHANES data to 
produce an unbiased national estimate. 
From 1999 to 2004, 29,402 individuals enrolled in the NHANES completed the interview and health 
examination.  As the objective of the present study was to investigate urinary phytoestrogens in relation to cancer, 
cardiovascular, and all-cause mortality, our analysis was confined to subjects who were ≥18 years and completed a 
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24-hour dietary recall, reducing the sample size to 17,061.  Urinary concentrations of phytoestrogens were measured 
among approximately one-third of total NHANES participants.  Subsampling in NHANES was performed to reduce 
participant burden and facilitate scheduling and completion of examinations.  All subjects in the subsample were 
randomly selected from the pool of total participants to obtain a nationally representative sample, with subsample 
weights calculated to account for probability of being selected into the subsample and additional non-response [39].  
Excluding subjects without data on urinary phytoestrogens left the cohort with 5,179 subjects, for whom 79 cancer 
deaths, 108 cardiovascular deaths, and 290 all-cause deaths were identified during a mean follow up of 
approximately 5 years (1999-2006).  The de-identified data analyzed in the present study are freely available in 
public domains, and the approval for such data analysis by the Institutional Review Board of Indiana University was 
sought but determined not to be applicable. 
Baseline data collection 
NHANES participants were interviewed to collect data on age, sex, race (non-Hispanic white, non-Hispanic 
black, and other race including multiracial), marital status (married or living with partner, widowed, divorced or 
separated, and never married), and education level (less than high school, high school graduate or equivalent, and 
more than high school).  Data were also collected on smoking status [never smokers (smoking 0 or <100 cigarettes 
in lifetime), former smokers (smoking ≥100 cigarettes in lifetime but not currently smoking), and current smokers], 
alcohol consumption (0 drink/week, <1 drink/week, and >1 drink/week), and nutrient intake through a 24-hour food 
recall.  Body mass index (BMI) (kg/m2) was calculated from height and weight measured during the medical 
examination portion of data collection. 
Urinary phytoestrogen measurement 
Phytoestrogen biomonitoring was accomplished by measuring urinary excretion of isoflavones (including 
daidzein, genistein, equol, and O-desmethylangolensin) and enterolignans (including enterodiol, and enterolactone) 
using high performance liquid chromatography (HPLC) with tandem mass spectrometric (MS/MS) detection [40].  
The methods for the collection and analysis of urine samples for phytoestrogen concentrations have been described 
in detail elsewhere [41].  Briefly, subjects were assigned a date and time to report to one of the Mobile Examination 
Centers to donate a urine sample.  Spot urine specimens were collected the morning after a recommended fast, 
processed, stored at -200C, and then shipped to the Division of Environmental Health Laboratory Sciences at the 
NCHS for analysis.  Urine samples were amended with stable isotope-labeled internal standards to improve method 
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accuracy and precision, incubated with a deconjugation enzyme to allow the quantification of individual 
phytoestrogens, extracted using solid phase extraction to remove interferences and improve sensitivity, and then 
analyzed using negative ion mode electrospray ionization HPLC-MS/MS, an assay with a high degree of specificity 
for each analyte [41]. 
Mortality follow-up 
 International Classification of Diseases 10th Revision (ICD-10) codes were used in the selected databases that 
recorded cause-specific deaths ascertained during follow-up through December 31, 2006 [37].  The underlying 
causes of death were grouped according to the guidelines provided by the NCHS.  The primary outcomes of the 
present study were cancer mortality (ICD-10 codes, C0-C97), cardiovascular mortality (ICD-10 codes, I00-I99), and 
all-cause mortality [42].  
Statistical analysis 
The study population was divided into tertiles based on individuals’ urinary concentrations of both total and 
each individual phytoestrogen to allow for an adequate number of subjects in each group.  Total phytoestrogens 
were calculated by summing up all of the individual phytoestrogens, with a similar calculation completed for both 
total isoflavones and total enterolignans.  Demographic, anthropometric, and lifestyle characteristics of subjects 
(including age, gender, race, BMI, education, smoking status, and alcohol intake) were compared by the tertiles of 
total urinary phytoestrogen (ng/ml) (tertile 1: 4 – 414; tertile 2: 415 – 1,047; tertile 3: 1,048 – 112,457).  Chi-square 
tests and analysis of variance were employed to compare differences in categorical and continuous variables among 
tertiles, respectively.  Urinary concentrations of total and individual phytoestrogens were summarized by medians 
and interquartile ranges.  Two-sided t-tests were used to compare them between groups using log-transformed 
values to account for skewed distributions. 
Cox proportional hazards regression was performed to calculate hazard ratios (HRs) and 95% confidence 
intervals (CIs) for cancer, cardiovascular, and all-cause mortality in relation to urinary phytoestrogens. Deaths from 
other causes were treated as censored events in the analyses. The time variable for the Cox models was defined as 
the time period from the initial NHANES interview date to the date of death or December 31, 2006, whichever 
occurred first.  The lowest tertile of urinary concentrations was the reference group to estimate HRs and 95% CIs for 
the two upper tertiles.  The multivariable models were adjusted for age, BMI, education, smoking status, total 
energy intake, sodium intake, and urinary creatinine.  Urinary excretion of creatinine was entered into the models to 
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account for urine dilution.  Gender, race, marital status, and intake of fruits, vegetables, alcohol, fat, and calcium 
were examined as potential confounders but not included in the final models because they were not significantly 
associated with any of outcomes of interest in univariate models or did not substantively alter any risk estimates for 
all outcomes considered (<10%).  No interactions tested were found to be statistically significant or exhibited clear 
patterns, and thus no interaction terms were included in the final model.  Factors that were tested for their 
interactions with urinary phytoestrogens in relation to each of the three outcomes included age, gender, BMI, 
education, smoking status, total energy intake, and sodium intake.  Linear trends across tertiles of phytoestrogen 
intake were tested by using the median in each tertile to create a continuous variable.  A two-sided p-value of <0.05 
was considered statistically significant.  SAS version 9.4 (Cary, NC) was used for all statistical analyses. 
Results 
Characteristics of study subjects are shown in Table 1.  Subjects were statistically significantly different across 
total phytoestrogen tertiles for gender, race, education, smoking status, and alcohol intake.  Those in the highest 
tertile of urinary phytoestrogens were more likely to be male, non-Hispanic white, have more years of education, 
and be never smokers, but were less likely to be obese and non-drinkers.   
Table 2 shows differences in urinary concentrations of total and individual phytoestrogens between subjects 
who died of total cancer, cardiovascular disease, and all causes and those who remained alive during follow up 
through the censor date (December 31, 2006).  The median urinary concentrations of total phytoestrogens were 
lower in individuals who died of each of the three outcomes examined than respective individuals who were alive.  
Similarly, lower urinary concentrations of total enterolignans were observed for subjects who died of cardiovascular 
disease and all causes, and lower urinary levels of enterolactone were found for those who died of all causes.  
Conversely, the median urinary concentrations of total isoflavones and daidzein were higher among individuals who 
died of cardiovascular disease and all causes than those who remained alive.  No significant differences in log-
transformed means of total and individual phytoestrogens existed between subjects who did and did not die of each 
of the three outcomes of interest. 
Risk estimates for each of the three outcomes examined in relation to urinary excretion of total and individual 
phytoestrogens are presented in Table 3.  After adjustment for confounders, total phytoestrogens and each of 
individual phytoestrogens were not associated with a significantly altered risk of death from total cancers.  A 
significantly increased risk of death from cardiovascular disease was found for higher urinary excretion of total 
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isoflavones (HR for tertile 3 vs. tertile 1: 2.14; 95% CI: 1.03, 4.47) and urinary daidzein (HR for tertile 3 vs. tertile 
1: 2.05; 95% CI: 1.02, 4.11).  Conversely, higher total enterolignan excretion was significantly associated with a 
reduced risk of death from cardiovascular disease (HR for tertile 3 vs. tertile 1: 0.48; 95% CI: 0.24, 0.97).  Similarly, 
a significantly reduced all-cause mortality was found for higher urinary excretion of total enterolignans (HR for 
tertile 3 vs. tertile 1: 0.65; 95% CI: 0.43, 0.96) and enterolactone (HR for tertile 3 vs. tertile 1: 0.65; 95% CI: 0.44, 
0.97). There was a suggestive threshold effect of urinary isoflavones and enterolignan on cardiovascular mortality 
and urinary isoflavones on all-cause mortality. 
To evaluate the possibility of reverse causality arising from preexisting chronic diseases, additional analyses 
were performed by removing individuals from the dataset who died within two years of enrollment into the study 
(n=24 for total cancer and n=43 for cardiovascular disease) [43,44].  An increased risk of cancer death was observed 
for subjects in the second tertile of urinary total isoflavones (HR: 2.62; 95% CI: 1.13, 6.10), but risk estimates for all 
other phytoestrogens remained insignificant.  An increased risk of cardiovascular death persisted for subjects in the 
third tertile of urinary total isoflavones (HR: 2.79; 95% CI: 1.10, 7.06), but an increased risk for individuals in the 
third tertile of urinary daidzein and a decreased risk for those in the third tertile of urinary total enterolignans (HR: 
0.39; 95% CI: 0.15, 1.00) were no longer significant.  The reduced risk of all-cause mortality disappeared for 
subjects in the third tertile of urinary total enterolignans and the third tertile of urinary enterolactone. 
Discussion 
The present study investigated the associations between urinary phytoestrogens and cancer, cardiovascular, and 
all-cause mortality using data collected from a nationally representative sample of the U.S. population.  It was found 
that urinary concentrations of total enterolignans were significantly and inversely associated with cardiovascular and 
all-cause mortality, whereas urinary concentrations of total isoflavones and daidzein were significantly and 
positively associated with cardiovascular mortality.  In addition, higher urinary concentrations of enterolactone were 
significantly associated with lower all-cause mortality. 
Genistein is a main isoflavone present in soy products and has been one of the most widely investigated 
phytoestrogen metabolites.  The present study did not show a significant association between urinary genistein and 
total cancer mortality, which was consistent with the results of several other studies in which genistein intake was 
not associated with the risk of different types of cancer [23,24,45].  Some studies have reported an inverse 
association between plasma concentrations of genistein and the risk of prostate and breast cancers [46,47].  A few 
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experimental studies revealed a protective effect of genistein on prostate cancer [48,49], whereas another 
experimental study reported an increased risk of colon cancer associated with genistein intake [50].  Collectively, all 
the studies discussed above suggest that dietary intake of individual isoflavones or lignans may exert different 
effects on individual types of cancer.  Given the small number of total cancer deaths (n=79) in the present study, it 
was not possible to examine cancer-specific associations with total and individual phytoestrogens, an intriguing 
question worthy of investigation in cohort studies with a larger number of cases of common cancers.  
Enterolactone is the main lignan metabolite in both urine and blood [11].  The urinary concentrations of this 
metabolite were found to reflect the habitual dietary intake of plant lignans [9].  As the precursors of enterolactone 
are detected in whole-grain products, legumes, seeds, fruits, and vegetables, the urinary concentrations of 
enterolactone are considered a biomarker for an overall healthy diet [23].  The present study showed low all-cause 
mortality associated with elevated urinary excretion of both total enterolignans and enterolactone.  The consumption 
of lignan-rich foods has been associated with a decreased risk of breast and prostate cancers in some studies [18] and 
an increased risk of prostate cancer in other studies [51].  The present study did not show a significant association 
between urinary excretion of total or individual enterolignans and total cancer mortality.  It has been found that 
enterolactone suppressed the proliferation and migration of prostate cancer cells [52], which suggests that 
enterolactone intake may reduce the risk of prostate and some other cancers.  The differential effects of 
enterolactone intake on the risk of different sites of cancer [18,51] may account in part for the null results observed 
for this compound in relation to total cancer mortality in the present study.  A significantly reduced risk of 
cardiovascular death associated with urinary excretion of total enterolignans was observed in the present study, 
which partially contributes to its inverse association with all-cause mortality. 
Experimental and epidemiologic data are scarce examining the influence of intake of total and individual 
phytoestrogens on cardiovascular health and disease.  One study showed that a lignan-rich diet was associated with 
elevated high-density lipoprotein concentrations and reduced triglyceride concentrations among U.S. adults [53].  
Increased serum concentrations of enterolactone have been associated with a reduced risk of acute coronary events 
and death from cardiovascular disease [54,55].  The results from these previous studies are consistent with those of 
the present study. This protective effect of enterolactone on cardiovascular disease may be partially attributable to 
the inverse associations of its high urinary concentrations with inflammation biomarkers (C-reactive protein and 
white blood cell counts), obesity, and metabolic syndrome in human studies [56-58].  Animal and in vitro studies 
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have offered additional mechanistic basis for the reduced cardiovascular mortality associated with elevated levels of 
urinary enterolactone [59-61].  Specifically, lignan complex [including secoisolariciresinol diglucoside (SDG)] 
isolated from flaxseed reduced the extent of hypercholesterolemic atherosclerosis and promoted its regression in 
rabbits [59,60].  SDG induced an elevated expression of vascular endothelial growth factor (VEGF) in human 
coronary arteriolar endothelial cells [61], and lack of VEGF led to ischemic cardiomyopathy in mice [62].  
Additionally, the present study showed an increased risk of cardiovascular death associated with urinary 
excretion of total isoflavones and daidzein.  The results of previous studies on these associations are conflicting.  A 
placebo-controlled, double-blinded trial of postmenopausal women supplemented with isoflavone soy protein 
showed no statistically significant effect on atherosclerosis progression [63].  Similarly, a meta-analysis of 
randomized controlled trials revealed that isoflavone supplementation did not improve endothelial function in 
postmenopausal women with high baseline flow-mediated dilation levels, but significant benefits were found for 
those with low baseline flow-mediated levels [64].  A cross-sectional study on middle-aged men in the U.S. reported 
that usual intake of isoflavones was not associated with a favorable cardiovascular risk profile [65].  A protective or 
null effect of isoflavones on cardiovascular disease that was observed in previous studies was inconsistent with a 
deleterious effect that was found in the present study.  This difference might have arisen from two reasons: 1) most 
previous studies were small dietary intervention trials among postmenopausal women; 2) in those studies, indicators 
of cardiovascular functions or biomarkers of cardiovascular lesions were examined; instead, the present study 
evaluated urinary excretion of total isoflavones and daidzein in relation to cardiovascular mortality among adult 
women and men of all ages.  The potential biological mechanisms for an increased risk of cardiovascular disease 
associated with urinary levels of isoflavones remain elusive.  However, genistein enhanced the gene expression of 
coagulation factors (prothrombin, factor VII, fibrinogen alpha, and fibrinogen beta) and C-reactive protein (all 
linked to cardiovascular disease risk) in ovariectomised rats [66]. 
 The present study has several advantages.  Exposure to total and individual phytoestrogens was evaluated by 
measuring their urinary concentrations. Urinary excretion of phytoestrogens is free of recall bias inherent in food 
frequency questionnaires and is an integrated reflection of phytoestrogen intakes from all sources, including those 
that may be inadequately represented in food composition databases.  For example, the most abundant sources of 
isoflavones in the diet are from foods containing soy products, such as tofu.  However, soy additives are found in 
some processed foods [67], and certain isoflavones are naturally present in lower concentrations in other foods such 
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as vegetables [68], fruits, and nuts [69].  Another theoretical advantage of measuring urinary phytoestrogens is that 
this assay can also capture phytoestrogen metabolites (e.g. equol and O-desmethylangolensin) produced by intestinal 
bacteria [70].  It is critical to determine amounts of exposure to specific phytoestrogens because they differ in their 
levels of biological activity [18].  The US Department of Agriculture has a food composition database for 
isoflavones but not for lignans [71], which does not allow us to calculate dietary intake of total phytoestrogens for 
participants in the NHANES.  The present study is one of the first studies that used urinary phytoestrogens as 
biomarkers of their dietary intake to evaluate the effect of these bioactive compounds on the risk of death from 
cancer and cardiovascular disease.  Most previous investigations of the effect of phytoestrogens on cancer risk were 
small case-control studies [51,72].  Another strength of the present study is that the analysis prospectively evaluated 
associations between urinary phytoestrogens and all-cause and cause-specific mortality.  The data used are based on 
a nationally representative sample with a relatively large between-person variation in urinary excretion of individual 
and total phytoestrogens. 
  Limitations of the present study need to be considered in the interpretation of obtained results.  A small number 
of events for both cancer mortality and cardiovascular mortality did not allow us to perform a stratified analysis by 
type of cancer or cardiovascular disease.  Future studies that incorporate a longer follow-up period may provide new 
insights into the etiology of cancers and cardiovascular diseases.  Lack of adequate power may explain the null 
associations between urinary phytoestrogens (especially isoflavones) and cancer mortality.  Spot urine was used to 
determine phytoestrogen concentrations, and the results of these measurements might be different from those using 
24-hour urine due to potential circadian rhythm.  To adjust for urine dilution, phytoestrogen concentrations were 
normalized to urinary creatinine levels by including urinary creatinine in the Cox models, a commonly used method 
[32,73], because creatinine is excreted by glomerular filtration at a relatively constant rate [74].  There have been no 
studies examining the correlation between spot and 24-hour urinary phytoestrogen concentrations.  However, the 
concentrations of phytoestrogens, particularly individual isoflavones, in spot urine have been reported to be 
statistically significantly correlated with their concentrations measured in serum [75].  In addition, urinary 
biomarkers of phytoestrogens were measured only once, and a single measurement might not accurately reflect 
individuals’ usual dietary intake due to within-person variation.  To capture habitual intake of phytoestrogens, 
repeated measurements of urinary excretion of this family of chemicals may be necessary, but data on such repeated 
measurements are not available from NHANES due to feasibility limitations. Therefore, it is possible that some 
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subjects might have been misclassified with regard to phytoestrogen intake because of a single measurement of 
urinary phytoestrogens and their modest correlations with dietary intake. 
Significant associations of urinary excretion of daidzein and total enterolignans with cardiovascular and/or all-
cause mortality disappeared after excluding subjects who died within two years of enrollment, which suggests that 
these associations reported in Table 3 may be partially ascribed to reverse causality due to the presence of 
subclinical disease. As NHANES did not exclude individuals with diseases at baseline, some individuals with 
clinical and/or subclinical disease might have been included in this study. Exact biological or physiological 
functions of most individual phytoestrogens remain to be elucidated. Therefore, caution needs to be exercised when 
interpreting their observed effects on disease risk in epidemiologic studies. Mortality data were analyzed in the 
present study. Therefore, obtained results may be less relevant to the etiology of total cancer and cardiovascular 
diseases than, and could not be directly compared with, those from analysis of incidence data because mortality of 
these two outcomes may be influenced by differences in access to and quality of medical treatment among study 
subjects. No significant differences existed in sex, race, BMI, and smoking status between the participants who 
donated a urine sample and those who did not.  Although the former were a little younger, attained a somewhat 
higher level of education, and were more likely to drink alcohol than the latter, the differences in these variables 
were small and the impact was considered inconsequential. 
In summary, the present study suggests that higher urinary concentrations of total enterolignans were associated 
with a reduced risk of death from cardiovascular disease.  Similarly, elevated urinary concentrations of both total 
enterolignans and enterolactone were associated with low all-cause mortality.  Conversely, higher urinary 
concentrations of total isoflavones and daidzein were significantly associated with an increased risk of death from 
cardiovascular disease and all causes. The observed results of total phytoestrogens need to be interpreted with 
caution due to potential differences in the physiological functions of individual phytoestrogens. It is important and 
timely to further investigate the associations of phytoestrogen intake, its biomarkers, and metabolic polymorphisms 
with the risk of total cancer, specific cancers, and cardiovascular disease in large prospective cohort studies as data 
generated from such studies may offer innovative avenues for the prevention of these major diseases among people 
across the world.  
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Table 1. Baseline characteristics of subjects by tertiles of urinary concentrations of total 
phytoestrogens (ng/mL) in the continuous National Health and Nutrition Examination 
Survey, 1999-2004 
 Tertile 1               Tertile 2           Tertile 3           
Characteristics (4-414) (415-1,047) (1,048–112,457)  
 n = 1,726 n = 1,727 n = 1,726 p-value 
Age [Mean (SD)] 44.7 (16.8) 45.5 (17.9) 44.8 (17.4) 0.28 
Gender (%)     
  Male 45.9 47.2 51.0 0.006 
  Female 54.1 52.8 49.0  
Race/Ethnicity (%)     
  Non-Hispanic White 70.7 71.2 72.5 0.029 
  Non-Hispanic Black 9.9 11.8 11.7  
  Other   19.4 17.0 15.8  
BMI [Mean (SD)] 28.3 (6.4) 28.2 (5.9) 27.7 (6.4) 0.004 
Education (%)     
  Less than High School 23.1 20.7 19.5 <0.001 
  High School Graduate 
or Equivalent 
27.3 27.5 22.9  
More than High School 49.6 51.8 57.6  
Smoking Status (%)     
  Never Smoker 48.2 51.4 53.6 <0.001 
  Former Smoker 22.9 24.1 25.3  
  Current Smoker 28.9 24.5 21.1  
Alcohol Intake (%)     
  0 drinks/week 20.2 21.0 16.7 0.025 
  < 1 drinks/week 41.9 42.9 46.1  
  > 1 drinks/week 37.9 36.2 37.3  
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Table 2. Differences in urinary concentrations of total and individual phytoestrogens (ng/mL) between subjects who did and did not die of total cancer, 
cardiovascular disease, or all-causes in the continuous National Health and Nutrition Examination Survey, 1999-2004a 
  Total Cancer Cardiovascular Diseases All Causes 
  Death          Survival                   Death          Survival                   Death          Survival                   
Phytoestrogens (n = 79) (n = 5,100) (n = 108) (n = 5,071) (n = 290) (n = 4,889) 
Total Phytoestrogen 607 (416, 1311) 679 (306, 1440) 437 (268, 1083) 682 (308, 1442) 531 (294, 1117) 687 (308, 1453) 
Isoflavone 160 (67, 294) 114 (44, 345) 163 (62, 260) 114 (44, 346) 139 (54, 286) 113 (44, 346) 
Genistein 32 (13, 88) 26 (9, 89) 28 (13, 79) 26 (9, 90) 31 (12, 79) 26 (9, 90) 
Daidzein 78 (28, 170) 56 (18, 191) 84 (32, 143) 56 (18, 191) 68 (21, 167) 56 (18, 191) 
Equol 8 (3, 19) 8 (2, 17) 6 (3, 14) 8 (2, 17) 7 (3, 18) 8 (2, 17) 
O-desmethylangolensin 3 (0, 16) 4 (1, 19) 5 (1, 21) 4 (1, 19) 3 (1, 16) 4 (1, 19) 
Enterolignan 437 (213, 809) 415 (148, 928) 299 (124, 706) 416 (149, 931) 347 (152, 750) 417 (148, 940) 
Enterodiol 53 (18, 112) 39 (14, 92) 32 (16, 66) 40 (14, 93) 33 (15, 86) 40 (14, 93) 
Enterolactone 371 (171, 743) 347 (104, 821) 240 (75, 622) 349 (105, 824) 289 (124, 628) 351 (104, 825) 
a Values are medians (interquartile ranges).  
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Table 3. HRs (95% CIs) for total cancer, cardiovascular, or all-cause mortality by tertiles of urinary concentrations of total and individual phytoestrogens in the continuous 
National Health and Nutrition Examination Survey, 1999-2004 
  Cancer Mortality Cardiovascular Mortality All-Cause Mortality 
 
No. of 
Cases 
Person- 
Years 
Creatinine-
Adjusted HR 
(95% CI)a 
Multivariable-
Adjusted HR   
(95 % CI)b 
No. of 
Cases 
Person- 
Years 
Creatinine-
Adjusted HR   
(95% CI)a 
Multivariable-
Adjusted HR     
(95 % CI)b 
No. of 
Cases 
Person- 
Years 
Creatinine-
Adjusted HR   
(95% CI)a 
Multivariable-
Adjusted HR      
(95 % CI)b 
Phytoestrogens (ng/mL) 
Total Phytoestrogen             
T1 (4-14) 25 1,820 Reference Reference 42 3,035 Reference Reference 102 7,250 Reference Reference 
T2 (415-1,047) 27 1,906 1.76 (0.93, 3.35) 1.41 (0.72, 2.75) 37 2,819 0.83 (0.47, 1.49) 0.58 (0.31, 1.09) 100 7,269 1.06 (0.76, 1.47) 0.78 (0.55, 1.12) 
T3 (1,048-112,457) 27 1,823 1.36 (0.68, 2.71) 1.18 (0.57, 2.46) 29 2,231 0.80 (0.42, 1.53) 0.63 (0.31, 1.28) 88 6,263 0.87 (0.60, 1.25) 0.69 (0.46, 1.02) 
p-trend   0.73 0.90   0.55 0.36   0.36 0.09 
Isoflavone             
T1 (1-58) 20 1,451 Reference Reference 31 2,346 Reference Reference 87 6,332 Reference Reference 
T2 (59-219) 30 2,081 1.96 (1.00, 3.87) 1.94 (0.96, 3.95) 37 2,698 2.07 (1.09, 3.92) 1.97 (0.98, 3.97) 100 7,119 1.46 (1.03, 2.08)* 1.34 (0.93, 0.95) 
T3 (220-55,729) 29 2,017 1.62 (0.80, 3.30) 1.67 (0.79, 3.52) 40 3,041 1.96 (1.01, 3.82) 2.14 (1.03, 4.47) 103 7,331 1.26 (0.87, 1.83) 1.22 (0.82, 1.82) 
p-trend   0.61 0.56   0.21 0.15   0.69 0.71 
Genistein             
T1 (0-13) 22 1,606 Reference Reference 33 2,455 Reference Reference 87 6,325 Reference Reference 
T2 (14-54) 25 1,765 1.57 (0.81, 3.06) 1.44 (0.73, 2.87) 38 2,828 1.76 (0.95, 3.24) 1.59 (0.83, 3.06) 97 6,968 1.60 (1.13, 2.28)* 1.44 (1.00, 2.08) 
T3 (55-25,700) 32 2,178 1.70 (0.88, 3.31) 1.46 (0.73, 2.93) 37 2,802 1.70 (0.89, 3.22) 1.39 (0.69, 2.80) 106 7,489 1.44 (1.00, 2.08) 1.17 (0.79, 1.74) 
p-trend   0.23 0.51   0.28 0.68   0.31 0.97 
Daidzein             
T1 (0-25) 20 1,441 Reference Reference 30 2,265 Reference Reference 82 5,948 Reference Reference 
T2 (26-115) 29 2,098 1.41 (0.72, 2.78) 1.29 (0.64, 2.63) 38 2,819 1.66 (0.88, 3.15) 1.48 (0.74, 2.97) 101 7,384 1.23 (0.86, 1.77) 1.09 (0.74, 1.60) 
T3 (116-29,200) 30 2,010 1.68 (0.86, 3.29) 1.77 (0.90, 3.49) 40 3,001 1.96 (1.02, 3.74) 2.05 (1.02, 4.11) 107 7,450 1.44 (1.01, 2.07) 1.43 (0.98, 2.08) 
p-trend   0.18 0.11   0.10 0.06   0.07 0.047 
Equol             
T1 (0-3) 22 1,532 Reference Reference 36 2,629 Reference Reference 93 6,666 Reference Reference 
T2 (4-11) 24 1,722 0.96 (0.48, 1.92) 0.94 (0.46, 1.91) 35 2,598 1.24 (0.67, 2.27) 1.40 (0.72, 2.74) 86 6,222 1.01 (0.70, 1.46) 1.06 (0.72, 1.56) 
T3 (12-17,200) 27 1,927 1.12 (0.58, 2.19) 1.12 (0.55, 2.27) 29 2,220 0.95 (0.48, 1.86) 1.22 (0.57, 2.60) 86 6,067 1.07 (0.74, 1.55) 1.18 (0.79, 1.76) 
p-trend   0.67 0.69   0.71 0.78   0.71 0.42 
O-desmethylangolensin             
T1 (0-1) 29 2,124 Reference Reference 32 2,374 Reference Reference 91 6,630 Reference Reference 
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T2 (2-9) 25 1,730 0.91 (0.49, 1.71) 0.78 (0.41, 1.48) 28 2,066 1.15 (0.60, 2.19) 1.07 (0.53, 2.15) 91 6,375 1.24 (0.87, 1.77) 1.12 (0.77 - 1.62) 
T3 (10-9,890) 23 1,569 0.83 (0.44, 1.56) 0.75 (0.38, 1.48) 40 3,025 1.50 (0.81, 2.77) 1.71 (0.87, 3.35) 93 6,725 1.13 (0.79, 1.63) 1.12 (0.76, 1.65) 
p-trend   0.59 0.58   0.19 0.07   0.90 0.72 
Enterolignan             
T1 (0-225) 27 1,999 Reference Reference 40 2,858 Reference Reference 101 7,106 Reference Reference 
T2 (226-691) 30 2,116 1.68 (0.90, 3.13) 1.43 (0.75, 2.73) 39 3,009 0.83 (0.47, 1.46) 0.55 (0.30, 1.02) 112 8,281 1.26 (0.91, 1.74) 0.99 (0.70, 1.40) 
T3 (692-85,847) 22 1,434 1.22 (0.62, 2.39) 1.05 (0.52. 2.14) 29 2,218 0.73 (0.39, 1.38) 0.48 (0.24, 0.97) 77 5,395 0.86 (0.60, 1.25) 0.65 (0.43, 0.96) 
p-trend   0.087 0.86   0.36 0.07   0.26 0.019 
Enterodiol             
T1 (0-20) 27 1,991 Reference Reference 38 2,805 Reference Reference 105 7,566 Reference Reference 
T2 (21-63) 22 1,586 0.94 (0.47, 1.88) 1.09 (0.54, 2.22) 38 2,961 1.15 (0.65, 2.04) 1.36 (0.74, 2.48) 93 6,877 0.92 (0.65, 1.29) 1.05 (0.73, 1.50) 
T3 (64-18,000) 28 1,835 1.60 (0.85, 3.01) 1.66 (0.85, 3.34) 30 2,177 0.92 (0.48, 1.77) 0.71 (0.87, 1.78) 88 6,060 0.97 (0.68, 1.37) 0.98 (0.67, 1.43) 
p-trend   0.08 0.10   0.69 0.52   0.95 0.85 
Enterolactone             
T1 (0-173) 25 1,790 Reference Reference 40 2,880 Reference Reference 102 7,177 Reference Reference 
T2 (174-595) 32 2,330 1.77 (0.96, 3.29) 1.52 (0.80, 2.90) 37 2,837 0.98 (0.56, 1.72) 0.68 (0.37, 1.26) 110 8,141 1.34 (0.97, 1.85) 1.09 (0.77, 1.54) 
T3 (596-85,300) 22 1,429 1.19 (0.60, 2.32) 1.01 (0.50, 2.05) 31 2,368 0.78 (0.41, 1.48) 0.54 (0.27, 1.07) 78 5,464 0.86 (0.59, 1.25) 0.65 (0.44, 0.97) 
p-trend   0.99 0.72   0.43 0.10   0.22 0.014 
HR, hazard ratio; CI, confidence interval. 
aAdjusted for urinary creatinine. 
bAdjusted for age, education, smoking status, body mass index, total energy intake, sodium intake, and urinary creatinine. 
 
